Consensus Omeros Corporation

Stocks

OMER

US6821431029

Biotechnology & Medical Research

Market Closed - Nasdaq 06:00:00 16/09/26 am AEST			5-day change	1st Jan Change
17.17 ^USD	-1.66%		-10.20%	-0.03%

02/09	Omeros Insider Sold Shares Worth $929,668, According to a Recent SEC Filing	MT
29/08	Omeros Insider Sold Shares Worth $282,094, According to a Recent SEC Filing	MT

Evolution of the Average Target: Omeros Corporation

Evolution of the Target Price: Omeros Corporation

Changes in Analyst Recommendations: Omeros Corporation

511117b098.SdyQCjKyQsH8ZSKxtAbHIEFaHMtGus0VBbVfRxBDDf0.OojhRHfQLLKSAlH_h2GJch5tKbgh6JlFSphsJlgMf6p-mdpwRfcyjZ0gUQ~88e7de0d7f7c70dd34a29e6df7270507

Analysts' recommendations: Omeros Corporation

15/10/25	Omeros Shares Surge Pre-Bell After Asset Purchase, License Deal With Novo Nordisk	MT
10/06/25	HC Wainwright Initiates Coverage on Omeros With Buy Rating, $9 Price Target	MT
16/03/23	UBS Adjusts Omeros Price Target to $4 From $2, Maintains Neutral Rating	MT
09/12/22	UBS Downgrades Omeros to Neutral From Buy, Adjusts Price Target to $2 From $12	MT
10/11/22	BofA Securities Downgrades Omeros to Underperform Rating From Neutral, Price Target is $3	MT
08/06/22	BofA Securities Downgrades Omeros to Neutral From Buy, Sets $4 Price Target	MT
19/01/22	Cantor Fitzgerald Adjusts Omeros' Price Target to $20 From $34, Reiterates Overweight Rating	MT
20/10/21	Omeros : HC Wainwright Adjusts Price Target on Omeros to $12 From $19, Maintains Buy Rating	MT
16/10/21	Omeros : UBS Adjusts Price Target on Omeros to $13 From $25 on Drug Filing Deficiencies, Maintains Buy Rating	MT
11/10/21	Omeros : Wedbush Suspended Coverage on Omeros	MT
08/10/21	Omeros : JPMorgan Downgrades Omeros to Underweight from Neutral	MT
07/10/21	Omeros : HC Wainwright Adjusts Omeros' Price Target to $19 from $32, Keeps Buy Rating	MT
05/10/21	Omeros : Maxim Downgrades Omeros to Hold from Buy	MT
02/10/21	Omeros : Wedbush Downgrades Omeros to Underperform From Neutral, Lowers PT to $5 From $18 After FDA Delays PDUFA For Narsoplimab	MT
02/10/21	Omeros : Maxim Group Downgrades Omeros to Hold From Buy	MT
27/09/21	Omeros : JPMorgan Starts Omeros at Neutral With $15 Price Target	MT
19/06/21	Omeros : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target	MT
26/04/21	Omeros : HC Wainwright Adjusts Omeros' Price Target to $32 From $34, Keeps Buy Rating	MT
02/02/21	Omeros : UBS Starts Omeros at Buy With $25 Price Target	MT
21/01/21	Omeros : HC Wainwright Adjusts Omeros' Price Target to $34 from $31, Keeps Buy Rating	MT
20/01/21	Omeros : Wedbush Adjusts Omeros' Price Target to $18 From $13, Maintains Neutral Rating	MT
05/12/20	Omeros : Maxim Adjusts Omeros' Price Target to $25 from $20, Keeps Buy Rating	MT
17/11/20	Omeros : Wedbush Adjusts Omeros' Price Target to $13 From $12, Maintains Neutral Rating	MT

More recommendations

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' Target price divergence	Objective/dr gap
OMEROS CORPORATION	-	+89%
WUXI APPTEC CO., LTD.		+17.76%
ARGENX SE		+17.76%
INSMED INCORPORATED		+59.76%
WUXI BIOLOGICS (CAYMAN) INC.		+18.28%
BIONTECH SE		+19.67%
GENMAB A/S		+15.96%
PHARMAESSENTIA CORPORATION		+17.42%
SUMMIT THERAPEUTICS INC.		+57.67%
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.		+28.78%
Average		+34.21%
Weighted average by Cap.		+25.02%